Cell Line Data Sheet for CHLA-20

Disease:	Neuroblastoma
Phase of Therapy:	Post-Chemotherapy (Progressive Disease)
Treatment:	Cisplatin, cyclophosphamide, doxorubicin, teniposide
Disease Stage:	4
Gender:	Female
Age at diagnosis:	24 months
Race:	N/A
Age at sample collection:	N/A
Source of Culture:	Primary tumor
Primary Tumor Site:	N/A
Date Established:	October 1988
MYCN Patient:	Non-amplified
MYCN Cell line:	N/A
TH mRNA:	Expressed
p53 functionality:	Functional
Telomere Mechanism:	N/A
ALK:	R1257Q
RNAseq:	N/A
WES:	N/A
Growth Conditions:	Please see Protocols section at https://www.cccells.org/protocols.php 5% CO_2, 20% O_2, 37.0°C
Media Formulation:	Please see Protocols section at https://www.cccells.org/protocols.php Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)
Doubling Time:	28 hours
Growth Properties:	Adherent, grows as loosely attached monolayer, numerous tight clumps
STR Profile:	May be obtained at https://strdb.cccells.org/
Notes:	COGcell.org has a diagnosis (pre-therapy) cell line available from this same patient– CHLA-15. The repository has a matching EBV lymphoblastoid cell line– COG-V-448

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.

Cell Line Data Sheet for CHLA-20

Cell Line Name: **CHLA-20**

References:

1. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. *Cancer Research*. 58:5396-5405,1998. PubMed ID: 9850071
https://cancerres.aacrjournals.org/content/58/23/5396.long

2. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. *Cancer Chemoth Pharm*. 45: 1-8, 2000. PubMed ID: 10647494
https://link.springer.com/article/10.1007%2FPL00006736

3. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide. *J Natl Cancer I*. 99: 1107-19, 2007. PubMed ID: 17623797
https://academic.oup.com/jnci/article/99/14/1107/938992

4. Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, Sposto R, Neuwelt EA, Reynolds CP: Sodium Thiosulfate (STS) administered six hours after cisplatin does not compromise anti-neuroblastoma activity. *Clin Cancer Res*. 14:533-540, 2008. PubMed ID: 18223229
https://clincancerres.aacrjournals.org/content/14/2/533.long

5. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatr Blood Cancer*. 56: 239-249, 2011. PubMed ID: 20922763
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/

(www.PPTPinvitro.org)

Cell Line Data Sheet for CHLA-20

Cell Line Name: **CHLA-20**

(10x magnification)



(10x magnification)



(20x magnification)

(20x magnification)